Diagcor Bioscience

What Diagcor Bioscience does

Diagcor Bioscience Incorporation Limited is a Hong Kong-based molecular diagnostics laboratory founded in 2006 as the first private MDx laboratory in the city. It operates as a wholly-owned subsidiary of Pangenia Inc (Pangenia Group) from a single laboratory facility at 10/F, Stelux House, 698 Prince Edward Road East, San Po Kong, Kowloon. The company specializes in non-invasive prenatal genetic testing and related DNA services, with a research team of 70-80+ bioscience experts drawn from institutions including Yale, Stanford, HKU, and CUHK. The company reports having analyzed over 500,000 clinical samples cumulatively and holds accreditations from the College of American Pathologists, Quality Control for Molecular Diagnostics, the Hong Kong Medical Laboratory Technologists Board, and ISO 9001.

DiagCor's product portfolio is anchored by non-invasive prenatal testing (NIPT) for chromosomal aneuploidies (GP1/GP2), a 49-disease monogenic disorder screening panel (DS1/2/3, in partnership with Genoma Laboratory), pre-eclampsia risk assessment under the DiagRIGHT sub-brand (MP1/2/3/X), Group B Streptococcus early screening (IGB), Fragile X carrier screening (AFE/MFX), non-invasive prenatal parentage testing (MBT), Y-chromosome DNA exclusion testing (MBE), and postnatal paternity testing. Underlying technologies are PCR and next-generation sequencing, applied to maternal blood samples to deliver non-invasive results. DiagCor holds multiple patents for its testing methodologies and reports a 99.99% accuracy on parentage testing.

The business model is fee-for-service laboratory testing with per-test unit pricing and quote-based pricing on application. Go-to-market combines a healthcare-provider referral channel (Hong Kong clinics and obstetrics/gynecology practices collect samples and forward them to the DiagCor lab) with a direct-to-consumer channel (company website, hotline, WeChat, Weibo). Customer segments are primarily pregnant women seeking prenatal screening, plus families and individuals requiring parentage verification. DiagCor is led by CEO Desmond Hau.

Name

Diagcor Bioscience

Legal name

Diagcor Bioscience Incorporation Limited

Website

https://diagcor.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Diagcor Bioscience is a Hong Kong-based molecular diagnostics laboratory founded in 2006, specializing in non-invasive prenatal genetic testing (NIPT), monogenic disorder screening, pre-eclampsia risk assessment, and DNA parentage testing using PCR and NGS technologies, serving pregnant women and families primarily in Hong Kong via clinic referrals and direct-to-consumer channels.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics (Prenatal Genetic Testing)

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Molecular diagnostics
• Prenatal genetic testing
• Non-invasive prenatal testing
• DNA parentage testing
• Carrier screening services

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Laboratory Testing Services: DiagCor operates as a molecular diagnostics laboratory providing fee-for-service genetic testing. Services include prenatal screening tests (NIPT, pre-eclampsia screening, Group B Streptococcus screening), parentage testing (prenatal and postnatal), Y-chromosome testing, and Fragile X carrier screening. Revenue is generated through one-time testing fees per test performed.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Diagcor Bioscience operates a Hong Kong-based clinical molecular diagnostics laboratory that performs non-invasive prenatal genetic tests on maternal blood samples using PCR and NGS technologies. Its product portfolio covers chromosomal aneuploidy screening (Down, Edwards, Patau syndromes), monogenic disorder screening, Fragile X carrier screening, pre-eclampsia risk assessment, Group B Streptococcus screening, Y-chromosome DNA exclusion testing, and non-invasive prenatal and postnatal parentage testing. Tests are delivered fee-for-service, primarily to pregnant women and families referred by Hong Kong obstetric clinics or contacting the lab directly.

Product overview

Diagcor Bioscience is a Hong Kong-based molecular diagnostics laboratory offering a comprehensive one-stop prenatal testing portfolio. The product suite centers on non-invasive prenatal testing (NIPT) services including chromosomal aneuploidy screening (GP1/GP2), monogenic disorder screening (DS1/2/3), and pre-eclampsia risk assessment (DiagRIGHT MP series). Related services include Y-chromosome DNA exclusion testing (MBE), non-invasive prenatal parentage testing (MBT), Fragile X carrier screening (AFE/MFX), and Group B Streptococcus screening (IGB). The company also offers postpartum paternity testing services (legal and non-legal use). All prenatal tests are non-invasive, requiring only maternal blood samples, with testing protocols based on PCR and next-generation sequencing (NGS) technologies.

Differentiator

Problem solved

Functional benefit

Brands

• DiagRIGHT: A brand under DiagCor for prenatal screening products including Pre-Eclampsia Risk Assessment (MP1/2/3/X) and Group B Streptococcus Early Screening.

Products and services

• Non-Invasive Prenatal Testing (GP1/GP2) Screens maternal blood for common fetal chromosomal aneuploidies — Down syndrome (T21), Edwards syndrome (T18), Patau syndrome (T13) — plus fetal sex chromosome detection using non-invasive PCR/NGS-based analysis. Target users are pregnant women, typically after ultrasound confirmation, referred by obstetricians or self-arriving at the DiagCor lab.
• Non-invasive Prenatal Monogenic Disorder Test (DS1/2/3) Advanced non-invasive prenatal screening covering 49 severe monogenic disorders from 29 gene mutations, including 5 common inherited recessive disorders and 44 de novo mutation disorders. Requires 10ml maternal blood and a paternal buccal swab; report delivered in 3 weeks. Aimed at pregnant couples seeking broad single-gene disorder screening in early pregnancy.
• DiagRIGHT Pre-Eclampsia Risk Assessment (MP1/2/3/X) Trademarked DiagRIGHT series for pre-eclampsia (pregnancy toxemia) risk assessment using maternal biomarker evaluation per FIGO and FMF guidelines; advertised to potentially reduce premature birth rates by up to 80%. Offered as MP1/MP3 early screening (11-14 weeks), MP2 mid-pregnancy, and MPX short-term prediction. Targets pregnant women seeking early prediction and prevention planning.
• DiagRIGHT Group B Streptococcus Early Screening (IGB) Early prenatal screening for Group B Streptococcus (GBS) bacteria in pregnant women to mitigate risk of neonatal infection during delivery. Delivered under the DiagRIGHT trademark. Intended for expectant mothers wanting to assess GBS colonization risk before birth.
• Fragile X Carrier Screening Test (AFE/MFX) Genetic carrier screening test that detects CGG repeat expansion in the FMR1 gene to identify carriers of Fragile X syndrome, the leading inherited cause of intellectual disability and autism. Aimed at women planning pregnancy or in early pregnancy, typically with family history considerations.
• Non-Invasive Prenatal Parentage Test (MBT) Non-invasive prenatal paternity test using maternal blood to determine biological parent-child relationship without fetal risk, available from 10 weeks gestation with 99.99% accuracy. Targeted at expectant parents and families needing early, safe prenatal paternity confirmation.
• Y-chromosome DNA Exclusion Test (MBE) Prenatal Y-chromosome-based exclusion test that compares fetal DNA markers from maternal blood with the alleged father's DNA sample to exclude or confirm paternal relationship. Requires prior Maternal Blood Y-DNA test showing detectable Y-DNA. Targets families and individuals investigating paternal relationship in early pregnancy.

Quantifiable outcome

• Reduce premature birth rate by up to 80% through early pre-eclampsia screening
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core and support.

• Pangenia Inc (新亞集團)coreStrategic or Co-development PartnerParent company and group affiliation. DiagCor is a wholly-owned subsidiary of Pangenia Inc (Pangenia Group). Pangenia Group provides corporate oversight and shared resources including access to management team and scientific leadership. DiagCor benefits from group synergies in biotech research and development.
• Genoma LaboratorysupportTechnology or IntegrationThird-party laboratory partnership for Non-invasive Prenatal Monogenic Disorder Test (DS1/2/3). Genoma laboratory provides testing services for the 49-type monogenic disorder screening panel, with DiagCor serving as the local representative and customer interface in Hong Kong.
• Hong Kong Clinics and Medical CenterscoreChannel Partner/ Reseller/ DistributorNetwork of Hong Kong medical clinics and health centers that collect patient samples and forward them to DiagCor laboratory for analysis. These partners follow strict chain of custody procedures and coordinate report delivery to patients.

Scale indicators5 records

Recent moves6 records

Direct peers

• BGI Genomics: China-based molecular diagnostics giant operating one of the world's largest NIPT platforms (NIFTY). Direct competitor to DiagCor in prenatal genetic testing across the Greater China region with significantly greater scale and lower unit cost.
• Natera: US-based cell-free DNA testing company with Panorama NIPT and Vistara single-gene NIPT. Directly comparable to DiagCor in technology (NGS-based cfDNA) and product mix, though operating globally and at materially larger scale.
• Berry Genomics: Beijing-headquartered NIPT and genetic testing company focused on prenatal screening in China. Competes directly with DiagCor's NIPT and expanded carrier screening offerings in the cross-border Hong Kong-mainland patient pool.

Broad incumbents

• Roche Diagnostics: Global diagnostics incumbent offering the Harmony NIPT test through its Sequenom acquisition plus a broad IVD menu. Competes with DiagCor at the platform/technology level and is a reference benchmark for an integrated diagnostics provider.
• Myriad Genetics: US-based genetic testing company with carrier screening and hereditary cancer tests. Comparable to DiagCor in monetizing proprietary genetic tests through physician channels and pursuing women's health/pregnancy indications.
• Kingmed Diagnostics: Large independent medical laboratory network in China offering a broad menu including prenatal and genetic testing. Overlaps with DiagCor's clinical lab service model and competes for cross-border prenatal testing volume from Hong Kong.
• Labcorp: US-headquartered clinical laboratory network offering MaterniT21 NIPT and a broad reproductive health menu. Comparable to DiagCor as a clinical lab with NIPT as a flagship offering, though operating at vastly greater scale and geographic reach.

Others

• Illumina: Dominant NGS platform provider whose sequencing technology underpins most NIPT and monogenic screening assays. Not a direct lab competitor but the critical enabling technology supplier for DiagCor and its peer laboratories.

Emerging players

• Sophia Genetics: Switzerland-based genomic analysis platform supporting clinical labs with NGS-based interpretation. Adjacent to DiagCor as an enabling platform for hospital-scale genetic testing and a potential partner/threat as labs digitize workflows.

Regional players

• Hangzhou Diying Biotechnology (EG Biotech): China-based NIPT and reproductive genetics provider. Comparable to DiagCor as a regional prenatal diagnostics laboratory serving the broader Chinese-speaking market with NGS-based aneuploidy and monogenic screening.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/diagcor
• Facebookfacebook.com/DiagcorBioscienceIncLtd
• LinkedInlinkedin.com/company/diagcor-bioscience-incorporation-limited

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagcor Bioscience